A new year is on the horizon, bringing a new, recognizable face to the top job at Teva. Four years after departing from rival Sandoz, Richard Francis is once again to take the CEO role at one of the generics and biosimilars industry’s leading players.
Francis will swap gene therapy for generics when he officially takes up the mantle at Teva on 1 January –...






